#1 Clinical Trials Search in Europe

ATIGOTATUG

Clinical trials are investigating ATIGOTATUG in people with extensive-stage small cell lung cancer. The study is checking whether ATIGOTATUG, given with other treatment, helps people live longer than the current comparison treatment. It is a Phase 3 trial focused on first-line therapy.

Table of contents

Trial overview

The clinical trial with ID NCT06646276 is studying ATIGOTATUG in people with extensive-stage small cell lung cancer (ES-SCLC).[1] The trial is authorised and planned as a Phase 3 study with 530 participants.[1]

This study is testing ATIGOTATUG as part of a fixed-dose combination with nivolumab, given together with chemotherapy, and comparing it with atezolizumab plus chemotherapy.[1] The study is focused on first-line therapy, which means the first main treatment used for the cancer.[1]

Who is being studied

The target population is participants with extensive-stage small cell lung cancer.[1] This means the trial is not for all lung cancers, but for this specific advanced form of small cell lung cancer.[1]

The study is looking at people who are starting treatment, because it is designed as first-line therapy research.[1] In simple terms, the trial is asking whether this treatment approach works well as the first treatment option.[1]

Treatments being compared

One study group receives ATIGOTATUG in a fixed-dose combination with nivolumab, along with chemotherapy medicines.[1] The chemotherapy drugs listed in the trial are etoposide and carboplatin.[1]

The comparison group receives atezolizumab with chemotherapy.[1] This head-to-head comparison helps researchers see whether the ATIGOTATUG-containing approach may offer better results than the current comparator treatment.[1]

Study design and phase

This is an interventional study, which means researchers assign treatments and then measure the results.[1] It is also a Phase 3 trial, which is usually done in a larger group to compare treatments and confirm benefits.[1]

The planned enrollment is 530 people.[1] That number shows the study is designed to include a fairly large group so the results can be compared across treatment groups.[1]

Main endpoint

The main endpoint is overall survival.[1] Overall survival means how long participants live after entering the study, starting from randomization, which is when people are assigned to a treatment group by chance.[1]

This endpoint matters because it shows whether one treatment approach helps people live longer than the other.[1] In this trial, that is the main way researchers will judge the treatment benefit.[1]

What this may mean for patients

For patients, this trial is testing whether a new treatment plan that includes ATIGOTATUG can improve outcomes when used at the start of care for ES-SCLC.[1] The study does not describe long-term results yet, so it is still focused on learning whether the new approach is better than the comparison treatment.[1]

Because it is a Phase 3 trial, the study is part of the later stages of clinical research.[1] The main question is simple: does the ATIGOTATUG-containing treatment help people live longer than atezolizumab with chemotherapy?[1]

Trial ID Phase Condition studied Status Enrollment
NCT06646276 Phase 3 Extensive-stage small cell lung cancer Authorised 530

FAQ

  • What is being studied in the ATIGOTATUG trial? The trial is studying ATIGOTATUG as part of a fixed-dose combination with nivolumab, given with chemotherapy. It compares this approach with atezolizumab plus chemotherapy.
  • Who can join this trial? The trial is for participants with extensive-stage small cell lung cancer. It is studying first-line therapy, which means treatment given as the first main treatment for the disease.
  • What phase is the ATIGOTATUG trial? This is a Phase 3 trial. Phase 3 studies usually compare a new treatment approach with a standard treatment in a larger group of people.
  • What is the main goal of the study? The main goal is to see whether the ATIGOTATUG-containing treatment helps people live longer than the comparison treatment. This is measured by overall survival.
  • How many people are planned for the study? The planned enrollment is 530 participants. That means the study aims to include about 530 people.

Ongoing Clinical Trials on ATIGOTATUG

  • Study Comparing BMS-986489 with Chemotherapy to Atezolizumab with Chemotherapy for First-Line Treatment in Patients with Extensive-Stage Small Cell Lung Cancer

    Recruiting

    3 1 1 1
    Investigated diseases:
    Investigated drugs:
    Austria Belgium Czechia France Germany Greece +5

Glossary

  • Extensive-stage small cell lung cancer (ES-SCLC): A form of small cell lung cancer that has spread more widely in the body.
  • First-line therapy: The first main treatment used after a person is diagnosed with a condition.
  • Phase 3: A later stage of clinical research that compares treatments in larger groups of people.
  • Interventional study: A trial where researchers give a treatment and study its effects.
  • Fixed-dose combination (FDC): Two medicines prepared together in a set amount.
  • Chemotherapy: Drug treatment used to kill cancer cells or slow their growth.
  • Overall survival: How long people live after they enter the study.
  • Randomization: A method of assigning participants to treatment groups by chance.
  • Atezolizumab: The comparison treatment used in this study together with chemotherapy.
  • Enrollment: The number of people planned to take part in a study.

References